CD33 and neoplasm: It has been reported that activated NKT cells can convert MDSCs into immune‐stimulatory APCs.22, 23 We have reported that reprogrammed lymphocytes containing CD25+ NKT cells can induce maturation of human CD33+CD11b+HLA‐DR− MDSCs into stimulatory CD33+CD11b−/lowHLA‐DR+ APCs, in vitro.24, 27 Given the inverse correlation between Gr1+CD11b+ cells and Gr1−/lowCD11b−/low APCs in naïve mice (Fig. 1A), we sought to determine the impact of tumor burden as well as AIT, containing conventional tumor‐specific T cells and CD25+ NKT cells, on the modulation of Gr1−/lowCD11b−/low APCs, in vivo.